Orientbio

오리엔트바이오 · 002630

Health Care Pharmaceuticals · KOSPI

Small-cap

Market cap US$41.5M (₩57.3B)

Overview

Orientbio breeds and supplies laboratory animals, purpose-raised mice, rats, and other species used in drug safety and efficacy testing, along with related research services such as pharmacokinetic studies and preclinical contract research.

Its customers are pharmaceutical companies, biotech firms, and research institutions that need certified animal models before advancing a drug candidate to human trials. The company is listed on KOSPI, South Korea's main stock exchange, and operates facilities designed to keep animals free from external contamination, meeting the good laboratory practice standards required for regulatory submissions.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025
Revenue · FY2025
US$21.3M
▲ +5.0% YoY
Operating profit · FY2025
−US$2.2M
Loss widened
Net income · FY2025
−US$9.6M
Turned to loss

Revenue

  • FY2023US$20.9M
  • FY2024US$20.3M
  • FY2025US$21.3M

Operating profit

  • FY2023US$1.1M
  • FY2024−US$468.1K
  • FY2025−US$2.2M

Net income

  • FY2023−US$9M
  • FY2024US$9.3M
  • FY2025−US$9.6M

Key ratios (FY2025)

ROE
-18.4%
Debt/Eq
18.0%
Op. margin
-10.5%
Net margin
-44.9%
Rev. YoY
▲ +5.0%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?

For informational purposes only. This is not investment advice, a recommendation, or a solicitation to buy or sell any security. Do your own research; any investment decision is your own responsibility.

Data from DART, Korea's official corporate-filing system. Data sourced from official DART filings. Accuracy is not guaranteed. Figures are as of the date shown. As of 2026-06-12 (KST). · FX: 1 USD ≈ ₩1,380 (2026-06-01).

Company summaries are generated and may contain errors; financial figures are mapped directly from official filings.